# The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

> **NCT02838810** · PHASE4 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** peginterferon alfa
- **DRUG:** Nucleoside analogues

## Key facts

- **NCT ID:** NCT02838810
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02838810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02838810, "The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02838810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*